Sara Carter Bailey approved for new drug czar as cannabis rescheduling debates grow amid strong public support and political resistance.
The U.S. cannabis industry stands at an inflection point as federal policy debates over rescheduling marijuana intensify. After decades of cannabis being listed as a Schedule I controlled substance — the federal designation reserved for drugs deemed to have no accepted medical use and a high potential for abuse — recent actions by the executive branch have signaled a willingness to reconsider the status. In 2025, the current president signed an executive order aimed at expediting the rescheduling of cannabis, potentially from Schedule I to Schedule III, a move acknowledging its medical use and ease research and regulatory burdens which have long hampered the industry. This shift has been buoyed by strong public support: polls consistently show a majority of Americans favor federal cannabis reform, even as some political leaders, including House Speaker Mike Johnson, have expressed resistance to broader legalization efforts. Federal rescheduling has become a flashpoint in the ongoing debate about drug policy and states’ rights. And to add something to the mix, Sara Carter Bailey approved for new drug czar, adding another level of unknown.
RELATED: 5 Ways Microdosing Cannabis Can Boost Work Performance
The U.S. Senate confirmed Bailey on 6 January 2026, as the new Director of the White House Office of National Drug Control Policy (ONDCP), often referred to as the federal “drug czar,” in a 52–48 vote. Her appointment comes at a consequential juncture for national drug policy, including cannabis reform. Bailey’s confirmation marks the first time a woman has led the ONDCP, placing her at the center of efforts to shape how the federal government approaches both illicit substances and regulated medical drugs.
Bailey’s background is unconventional for the post. She built her career as an investigative journalist, covering drug trafficking, national security, and cartel operations, including time as a contributor to national news outlets. She has never before held public office, nor does she have formal training in public health, law enforcement, or drug policy — a point which drew scrutiny from some senators during her confirmation process. Critics questioned her qualifications, while supporters highlighted her on-the-ground reporting experience and understanding of the complex landscape of illegal narcotics.
On issues directly affecting the cannabis industry, Bailey has left a mix of signals. During her confirmation hearing, she described cannabis rescheduling as a “bipartisan issue” and emphasized federal policy should be informed by “research and data” as the administration evaluates next steps. She also acknowledged past public comments supporting medical cannabis, saying she does not “have any problem if it’s legalized and monitored,” particularly for therapeutic use. However, as the incoming head of ONDCP, she has stopped short of advocating specific policy changes, noting her role requires compliance with existing federal law and collaboration with interagency partners.
RELATED: There’s No Known Cure For Arthritis, But Marijuana Works Wonders
Industry observers and advocates will be watching closely to see how Bailey’s tenure influences the cannabis sector. Rescheduling to Schedule III could remove significant legal and financial obstacles for medical cannabis businesses, including access to banking services and federal research opportunities. As ONDCP director, Bailey can play a key role in advising the president and shaping the interagency strategy on drug scheduling, public health education, and enforcement — all of which could either accelerate or complicate the pace of federal cannabis reform. Her path forward will require balancing statutory responsibilities with the growing momentum for change among lawmakers, industry stakeholders, and the public.
